Optometrists may not surgically repair macular holes, but they play a crucial role in managing visual outcomes in these ...

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

(RTTNews) - EyePoint Pharmaceuticals, Inc. (EYPT), Wednesday announced positive six-month results from the ongoing Phase 2 VERONA clinical trial, evaluating Duravyu for the treatment of diabetic ...

Diabetic macular edema remains an important cause of vision loss among patients with diabetes mellitus. Improved control of blood pressure and blood sugar, as well as photocoagulation, are ...

Novartis is running out of options in its bid to defend oral muscular sclerosis therapy Gilenya from early generic competition in the US. The US Court of Appeals for the Federal Circuit (CAFC ...

Macular degeneration is very common and affects an estimated 19.8 million people in the United States. Approximately one in 10 Americans age 50 and older have an early form of the disease and as many ...

today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME). “OCU200 has the potential to change the treatment landscape for DME ...

Ocugen announced the first patient in its OCU200 phase 1 clinical trial for diabetic macular edema (DME) has been dosed. The company describes OCU200 as a “recombinant fusion protein that consists of ...

Genome-wide association analyses identify distinct genetic architectures for age-related macular degeneration across ancestries. Nature Genetics , 2024; 56 (12): 2659 DOI: 10.1038/s41588-024-01764 ...